Abstract
Background
patients with acute AECOPD show an abrupt worsening of baseline ventricular function and pulmonary hypertension, using clear predictors or markers for severity in such patients is critical to be early stratified and properly managed.
Aim
Assess the value of BNP as A predictor for severity in patients with AECOPD represented by need for intensive care admission, invasive and non-invasive mechanical ventilation, pulmonary hypertension, hospital and 3 months mortality.
Study design
Prospective study
Methods
A prospective Cohort study in tertiary level hospital conducted on 88 patients with AECOPD and 88 healthy control subjects, patients were divided into 2 subgroups: ICU admitted and ward admitted Patient were subjected to clinical, electrocardiographic, radiological and laboratory evaluation and observation of the clinical course during admission and 3 months following hospital discharge.
Results
The study revealed higher BNP in AECOPD patients compared with healthy control subjects and in ICU admitted compared with ward patients (P, 0.001). positive correlation with age, smoking index, Paco2, SPAP, RVD, need for ICU , IMV, hospital stay and overall Mortality (r coefficient: 0.398, 0.533, 0.605, 0.635, 0.732, -0.617, 0.577, 0.728 0.030, respectivly), we revealed negative correlation with ABGs parameters (Pao2, PH and o2 saturation), with r. coefficient of (-0.616, -0.609, -0.630, respectively), linear regression revelled that BNP is significant predictors for ICU admission , ROC curve revealed that BNP more than 425pg/ml had sensitivity , specificity of (70.8% and, 100%) to predict need for ICU admission.
Conclusion
BNP may be considered as an accessible, useful, non-invasive and low-cost marker of severity COPD exacerbations.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.References
Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26:1887–1894.
Siafakas NM, Anthonisen NR, Georgopoulos D, Bshouty Z, Vestio J, et al. Acute exacerbations of chronic obstructive pulmonary disease. Lung Biology in Health and Disease series. New York, NY:Marcel Dekker 2003; 183.
Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12:315–321.
Rutten FH, Maarten M, Willem J, Grobbee DE, Hoe AW. Heart failure and chronic obstructive pulmonary disease:an ignored combination. Eur J Heart Fail 2006; 8:706–711.
Wu AH. B-type natriuretic peptide and its clinical utility in patients with heart failure. MLO Med Lab Obs 2001; 33:10–14.
Ishii J, Nomura M, Ito M, Naruse H, Mori Y, Wang JH, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000; 301:19–30.
Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43:764–770.
Medina AM, Marteles MS, Saiz EB, Martines SS, Laiglesia FR, Rodríguez JN, et al. Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. Eur J Intern Med 2011; 22:167–171.
Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133:1088–1094.
Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66:764–768.
Global Initiative for Chronic Obstructive Lung Diseases. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2016 Available at: http://www.goldcopd.com.
Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932–946.
Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32:1371–1385.
Davie NJ, Crossno JT, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization:contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 2004; 286:L668–L678.
Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling:cellular and molecular mechanisms. Circ Res 2006; 9:675–691.
Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30:993–1013.
Abraham AS, Cole RB, Green ID, Hedworth-Whitty RB, Clarke SW, Bishop JM. Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studies by serial observations during recovery. Circ Res 1969; 24:51–60.
Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease and the right heart. Chest 2004; 126:1330–1336.
Chi SY, Kim EY, Ban HJ, Oh IJ, Kwon YS, Kim KS, et al. Plasma N-terminal pro-brain natriuretic peptide:a prognostic marker in patients with chronic obstructive pulmonary disease. Lung 2012; 190:271–276.
Mallawany H, Mahmoud MI, Morsi TS, El-Shiekh RM. Role of N-terminal pro B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease. Egypt J Chest Dis 2014; 63:57–65.
Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with car pulmonale. Respir Med 1999 93:507–514.
Lang CC, Coutie WJ, Struthers AD, Dhillon DP, Winter JH, Lipworth BJ. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci 1992 83:529–533.
Hoiseth AD, Omland T, Hagve TA, Brekke PH, Soyseth V. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD. Resp Res 2012; 13:97.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Abdelnaby, N.K., Shabana, H.A. & Arafat, W.R. B-type natriuretic peptide as a predictor of severity in admitted patients with acute exacerbation of COPD. Egypt J Bronchol 13, 289–297 (2019). https://doi.org/10.4103/ejb.ejb_90_18
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/ejb.ejb_90_18